関連する実験動画
Updated: Sep 9, 2025

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.8K
ネフロロジーの臨床試験の将来の設計: 方法論的革新と計算能力の統合
Camillo Tancredi Strizzi1,2, Francesco Pesce1,3
1Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Sensors (Basel, Switzerland)
|August 28, 2025
まとめ
人工知能のような 革新的な試験設計や 計算ツールが 腎臓疾患の研究の進出に不可欠です これらの方法を統合することで 腎臓学の臨床試験における課題を克服することで 治療の開発を加速します
科学分野:
- 腎臓科
- 臨床試験の方法論
- コンピュータ生物学
背景:
- 腎臓学の臨床試験は 進行が遅い,患者異質性,採用の困難といった課題に直面します
- 治療の進歩により 症例の発生率が低下し 伝統的な治験の設計を複雑にする"成功のパラドックス"が生まれました
- 腎臓病の治療開発を加速するには 継続的な試験上の障害を克服する必要があります
研究 の 目的:
- 腎臓学の臨床試験における持続的な課題をレビューする.
- 試験の効率と精度を向上させるための方法論的革新と計算ツールを探求する.
- 人工知能,AR,CTGAN,シリコ試験,デジタルヘルスケア技術の腎臓疾患研究への影響をまとめます.
主な方法:
- ネフロロジー試験の課題とイノベーションに焦点を当てた物語の文献レビュー
- 人工知能 (AI),拡張現実 (AR),条件付き表型生成対抗ネットワーク (CTGAN),およびシリコ臨床試験 (ISCT) を含む計算ツールの分析.
- 適応的設計,実用的な試験,現実世界の証拠,代替エンドポイントなどの方法論的イノベーションの検討.
主要な成果:
- 適応的な設計や実用的な証拠などの 方法論的革新により 試験の柔軟性と関連性が向上します
- AI と ISCT を含む計算ツールでは,試験設計,患者層分化,データ分析,シミュレーションの最適化に重要な可能性があります.
- 拡張現実 (AR) は手順の精度を改善し,CTGANはデータ不足に対処することができます.
結論:
- 方法論的および計算的イノベーションの連携は,腎臓学の臨床研究の将来にとって不可欠です.
- この統合的アプローチは より効率的で正確な 患者中心の腎臓疾患試験を約束します
- データの品質,検証,規制,倫理に関する障壁を取り除くことは,成功するために不可欠です.
関連する概念動画
Clinical Trials
7.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
7.8K
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Chronic Kidney Disease III: Interprofessional Care
77
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
77
Renal Drug Clearance: Comparison Between Renal Excretion Methods
267
Renal clearance is a critical parameter encompassing kidney filtration, secretion, and reabsorption processes. It is calculated using a specific equation to determine the rate at which the kidneys clear a drug.
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
267
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Renal Drug Clearance: Overview
325
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
325

